The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer

Lee, Seul; Kim, Yun Hwa; Kim, Seung‐Chul; Joo, Jong Kil; Seo, Dong Suh; Kim, Ki Hyung; Lee, Kyu Sup

doi:10.5468/ogs.2018.61.5.615

Cited by 22 publications

(19 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breast cancer is the second leading cause of cancer mortality among women, after lung cancer. According to the American Cancer Society, approximately 1.3 million women worldwide are diagnosed with breast cancer annually, and > 465,000 women die of this disease [1].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of transvaginal ultrasound in detection of endometrial changes in breast cancer patients under hormonal therapy

Hetta

Samy

Romeih

et al. 2019

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background: The aim of the study is to evaluate the role and efficacy of transvaginal ultrasound in detection of endometrial changes in breast cancer patients under hormonal therapy in correlation with histopathological results of endometrial biopsies. Fifty patients with breast cancer under tamoxifen were subjected to transvaginal ultrasonography, and the results are compared with histopathological results of endometrial biopsies from March 2018 to November 2018. Results: Twenty-two patients (44%) had normal regular endometrium, and twenty-eight patients (56%) had abnormal ultrasonographic appearance with different types of pathology; there were 24 patients (85.7%) with endometrial abnormality and 4 patients (14.3%) with adnexal pathology. The twenty-four patients with endometrial abnormality were as follows: 10% endometrial atrophy, 4% endometrial carcinoma, 14% endometrial hyperplasia, and 7% endometrial polyp with sensitivity of 92.9% and accuracy of 96% in comparison to histopathology results. Conclusion: We found in our study that transvaginal ultrasonography is a sensitive and rather specific method to evaluate the endometrial lesions, so we concluded that it is a necessary screening tool for detection of endometrial abnormalities in breast cancer patients under hormonal therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Postoperative adjuvant systemic therapy prolongs survival in selected women with breast cancer and reduces the odds of death by 25% per year [1].…”

Section: Introductionmentioning

confidence: 99%

Role of transvaginal ultrasound in detection of endometrial changes in breast cancer patients under hormonal therapy

Hetta

Samy

Romeih

et al. 2019

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

show abstract

“…6b) [13,14]. Although recent reports also pointed out the stimulatory effects TAM on the ovarian function [16,17], its precise incidence rate remains unclear. The positive rate of OHS among groups A-C (25.1%) was slightly higher than the ratio estimated in our previous report [14].…”

Section: Discussionmentioning

confidence: 99%

Ovarian hyperstimulation closely associated with resumption of follicular growth after chemotherapy during tamoxifen treatment in premenopausal women with breast cancer: a multicenter retrospective cohort study

et al. 2020

View full text Add to dashboard Cite

Background: We previously reported that tamoxifen (TAM)-induced ovarian hyperstimulation (OHS) is associated with high serum concentrations of estradiol in premenopausal women with breast cancer. To investigate risk factors for TAM-induced OHS, we performed a retrospective multicenter study. Methods: Premenopausal patients who received surgical therapy for endocrine-dependent breast cancer (n = 235) were recruited in this study and classified into 4 groups: group A, treated with TAM alone; group B, TAM treatment after 2-year-combined therapy with a gonadotropin-releasing hormone (Gn-RH) agonist; group C, TAM treatment after chemotherapy; group D, 5-year-combined therapy with TAM and a Gn-RH agonist. A serum estradiol value of more than 300 pg/mL or mean follicular diameter of more than 30 mm was defined as OHS. Results: The incidence of OHS in group A (n = 13/26, 50.0%) was significantly higher than those in group B (n = 17/ 63, 27.0%), group C (n = 20/110, 18.2%), and group D (n = 0/36, 0%). The incidence of OHS was significantly correlated with aging, and the median serum concentration of estradiol in the presence of OHS was 823.0 pg/mL. The incidence of OHS (less than 47 years old) was 62.5% in group A, 48.6% in group B, and 28.2% in group C, respectively. Notably, the incidence rate of OHS following amenorrhea in group C (n = 13/20, 65.0%) was significantly higher than that in group B (n = 1/17, 5.9%). Conclusions: These findings indicate that the onset of OHS following amenorrhea was common in the postchemotherapeutic group, while its ratio was low in the group after Gn-RH analog treatment, suggesting that combined treatment-based management involving TAM therapy is necessary for premenopausal patients with breast cancer.

show abstract

“…The drug shows anti-oestrogenic activity on breast and oestrogenic effects on uterus, ovaries, bone, liver and cardiovascular system 2,5 . Tamoxifen may cause endometrial thickening 6,7,8 , endometrial hyperplasia 6,7,9,10 , increased uterine volume 11,12,13 , endometrial polyps 6,10 , increase in the size of uterine leiomyomata 7 , endometriosis 14 , ovarian cysts 6,14 . The most serious adverse effect of Tamoxifen is risks of developing endometrial cancer 5,10,15,17,18 and uterine sarcoma 7,10,17 .…”

Section: Introductionmentioning

confidence: 99%

Sonographic Study of Female Pelvic Organs in Breast Cancer Patients Taking Tamoxifen: Clinical Correlation

Parveen

Rahman

Sarker³

et al. 2020

J Curr Adv Med Res

View full text Add to dashboard Cite

Background: As most of breast cancer patients are treated with Tamoxifen, different effects of this drug in patients should be evaluated since no such study is carried out in Bangladesh till date. Objective: The purpose of the present study was to evaluate sonographic changes of female genital organs in breast cancer patients treated with Tamoxifen and to correlate these changes with duration of Tamoxifen treatment and gynecological symptoms. Methodology: This randomized double-blind clinical trial was carried out in Delta Medical College Hospital, Dhaka, Bangladesh from May 2017 to April 2018 for a period of one (1) year. The participants were breast cancer patients which were divided into three groups named as group I patients. The patients of these group were on Tamoxifen therapy. The patients of group II were without Tamoxifen therapy. The patients of group III had completed Tamoxifen therapy. All participants underwent ultrasonography. Results: Patients receiving Tamoxifen therapy had significantly more thickened endometrium compared to other groups (26.6% in group I, 5% in group II and3% in group III). Similarly, abnormal sonographic findings and mean uterine volume were higher in group I compared to other two groups. Endometrial thickness and uterine volume showed significant positive correlation with duration of Tamoxifen therapy (p <0.0001). The endometrial thickness and uterine volume greatly increased after two years of Tamoxifen therapy while it was reverse in group III. Gynecological symptoms had no significant relations with sonographic abnormalities and thickened endometrium. Conclusion: Tamoxifen therapy is associated with increased endometrial thickness, uterine volume and abnormal sonographic findings, compared to patients without Tamoxifen or completing Tamoxifen therapy. Journal of Current and Advance Medical Research 2020;7(1): 17-23

show abstract

The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer

Cited by 22 publications

References 16 publications

Role of transvaginal ultrasound in detection of endometrial changes in breast cancer patients under hormonal therapy

Role of transvaginal ultrasound in detection of endometrial changes in breast cancer patients under hormonal therapy

Ovarian hyperstimulation closely associated with resumption of follicular growth after chemotherapy during tamoxifen treatment in premenopausal women with breast cancer: a multicenter retrospective cohort study

Sonographic Study of Female Pelvic Organs in Breast Cancer Patients Taking Tamoxifen: Clinical Correlation

Contact Info

Product

Resources

About